Form D · Pharmaceuticals

Reviva Pharmaceuticals, Inc.

Santa Clara, CA · CIK 0001552470

Offering snapshot reported Jul 25, 2016 · SEC filing

Reported sold
$1.15M
Offering amount: $5M
Investors reported
16
Form D · investor count
Minimum accepted
$25K
Reported outside-investor minimum
First sale
Jul 11, 2016
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jul 25, 2016Initial$1,154,087No comparison16SEC filing
Jun 25, 2014Initial$15,831,541No comparison47SEC filing
Mar 21, 2013Initial$12,039,776No comparison82SEC filing
Aug 20, 2012Initial$7,624,840No comparison71SEC filing

Offering details

Securities
Debt, Other
Exemptions
06c
Duration over one year
No
Business combination
No
Sales commissions
$150K (estimated)
Finders' fees
$0
Form D file number
021-267657
Issuance of Convertible Promissory Notes, the Preferred Stock issuable upon conversion thereof and the Common Stock issuable upon conversion thereof.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC375Rodman & Renshaw, a unit of H.C. Wainwright & Co, LLC · CRD 375

Source: Form D, filed Jul 25, 2016. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Laxminarayan Bhat Director, Executive
Marc Cantillon Executive
Sarvajna Dwivedi Director
Pedr Jensen Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
3900 Freedom Circle, #101
Santa Clara, CA, 95054